CK-Dmineral and bone disorder: Core curriculum 2011

American Journal of Kidney Diseases

Volumn 58, Issue 6, 2011, Pages 1022-1036

  Moorthi, Ranjani N ^a   Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; COLLAGEN TYPE 1; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; PROTEOGLYCAN; SEVELAMER; SODIUM THIOSULFATE; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR RUNX2; CHELATING AGENT; FIBROBLAST GROWTH FACTOR; LANTHANUM; POLYAMINE; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCINOSIS; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CANCELLOUS BONE; CARTILAGE CELL; CHRONIC KIDNEY DISEASE; CORTICAL BONE; DIALYSIS; DIETARY INTAKE; EPIPHYSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY TUBULE ABSORPTION; MESENCHYME CELL; MINERAL DEFICIENCY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OXYGEN THERAPY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; URINARY EXCRETION; VITAMIN D DEFICIENCY; BLOOD; CHRONIC KIDNEY FAILURE; KIDNEY; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY;

BONE DISEASES; CALCINOSIS; CALCIPHYLAXIS; CALCITRIOL; CALCIUM; CHELATING AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; LANTHANUM; PARATHYROID HORMONE; PARATHYROIDECTOMY; PHOSPHORUS; POLYAMINES; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 81755165861     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.08.009     Document Type: Article

References (74)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130.
2. Moe SM. Chapter 8: Chronic Kidney Disease-Mineral Bone Disorder, Chronic Kidney Disease, Dialysis, and Transplantation, edited by Himmelfarb J and Sayegh M. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2010:98-114.
3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
4. Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14(1):3-12.
5. Moe SM, Sprague SM. Chapter 52: mineral bone disorders in chronic kidney disease. In:Brenner and Rectors The Kidney. 8th ed. Philadelphia, PA:WBSaunders Company; 2007:1784-1807.
6. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(4)(suppl 3): S1-S201.
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8): 2208-2218.
8. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
9. Institute of Medicine report dietary reference intakes for calcium and vitamin D 2010. http://www.iom.edu/Reports/ 2010/Dietary-Reference-Intakes-for- Calcium-and-Vitamin-D/ Report-Brief.aspx. Accessed January 14, 2011.
10. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50-62.
11. Moe SM. Confusion on the complexity of calcium balance. Semin Dial. 2010;23(5):492-497.
12. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
13. Qazi RA, Martin KJ.Vitamin D in kidney disease: pathophysiology and the utility of treatment. Endocrinol Metab Clin North Am. 2010;39(2):355-363.
14. Tomida K, Hamano T, Mikami S, et al. Serum 25- hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone. 2009;44(4):678-683.
15. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21(9):1427-1435.
16. Zidehsarai MP, Moe SM. Review article: chronic kidney disease-mineral bone disorder: have we got the assays right? Nephrology (Carlton). 2009;14(4):374-382.
17. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010;5(10):1860-1866.
18. Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 2006;69(10): 1852-1857.
19. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millenniumanalysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26(6):1368-1376.
20. Ott SM. Review article: bone density in patients with chronic kidney disease stages 4-5. Nephrology (Carlton). 2009;14(4): 395-403.
21. Ott SM. Bone histomorphometry in renal osteodystrophy. Semin Nephrol. 2009;29(2):122-132.
22. Barreto FC, Barreto DV, Liabeuf S, et al. Effects of uremic toxins on vascular and bone remodeling. Semin Dial. 2009; 22(4):433-437.
23. Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6(12):723-735.
24. Giachelli CM. The emerging role of phosphate in vascular calcification [published online ahead of print January 14, 2009]. Kidney Int. 2009;75(9):890-897.
25. Jahnen-Dechent W, Schäfer C, Ketteler M, et al. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008;86(4):379-389.
26. Ketteler M, Biggar PH. Review article: getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease. Nephrology (Carlton). 2009;14(4): 389-394.
27. Lau WL, Festing MH, Giachelli CM. Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost. 2010;104(3): 464-470.
28. Liu Y, Shanahan CM. Signalling pathways and vascular calcification. Front Biosci. 2011;16:1302-1314.
29. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213-216.
30. Noureddine L, Landis M, Patel N, et al. Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clin Nephrol . 2011;75(6):485-490.
31. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol . 2010;21(10):1637- 1640.
32. Shao JS, Cheng SL, Sadhu J, et al. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010;55(3):579-592.
33. Sood AR, Wazny LD, Raymond CB, et al. Sodium thiosulfatebased treatment in calcific uremic arteriolopathy: a consecutive case series. Clin Nephrol 2011:75(1):8-15.
34. Fadem SZ, Moe SM. Management of chronic kidney disease mineral-bone disorder. Adv Chronic Kidney Dis. 2007;14(1): 44-53.
35. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int. 2010;78(2):146-151.
36. Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):535-539.
37. Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKDMineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010;55(5):773-799.
38. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification- results from the BRiC Study. Nephron Clin Pract. 2008;110(4):c273-c283.
39. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438-441.
40. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815-1824.
41. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252.
42. Chertow GM, LevinNW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300.
43. DHaese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003;85:S73-S78.
44. Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405-412.
45. Freemont AJ, Hoyland JA, Denton J, et al. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005;64(6):428-437.
46. Malluche HH, Siami GA, Swanepoel C, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol. 2008;70(4):284-295.
47. Pierratos A. Daily (quotidian) nocturnal home hemodialysis: nine years later. Hemodial Int. 2004;8(1):45-50.
48. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis. 2008;51(6): 952-965.
49. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72(10):1255-1261.
50. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51(3):445-454.
51. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-1137.
52. Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: a randomized- controlled trial. Hemodial Int. 2010 14; (2): 174-181
53. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43(5):877-890.
54. Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2):263-276.
55. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358-363.
56. Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis. 2009;53(3):408-416.
57. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397-403.
58. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67(5):929-936.
59. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613-1619.
60. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, FinnW. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009;4(1):178-185.
61. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):512-518.
62. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27(1):36-43.
63. Moe SM. Vitamin D, cardiovascular disease, and survival in dialysis patients. J Bone Miner Res . 2007;22(suppl 2):V95-V99.
64. Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):512-518.
65. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483-1490.
66. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Eng l J Med. 2003; 349(5):446-456.
67. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16(4):1115-1125.
68. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858- 1865.
69. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516-1525.
70. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 2010;78(6):578-589.
71. Brown EM. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR). Biochem Pharmacol. 2010;80(3):297-307.
72. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793-1800.
73. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE Study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis [published online ahead of print December 8, 2010]. Nephrol Dial Transplant.
74. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66(5):2010-2016.